News
NIH inventors have developed a new strategy of using Interleukin 24 (IL-24) to target the whole T-helper 17 cells (Th17) lineage and thus achieve improved efficacy in therapy of Th17-relevant autoimmune diseases such as uveitis, multiple sclerosis, rheumatoid arthritis, and Crohn’s disease. The Th17
The 2012 Deals of Distinction™ Award was presented to National Institutes of Health (NIH) along with the University of Illinois at Chicago (UIC), who jointly own one patent family, and to Gilead Sciences (Gilead) for license agreements granted to the Medicines Patent Pool, a newly established
In a recently released report, the NIH details its plans for Accelerating Technology Transfer and Commercialization in Support of High Growth Business. The Plan is a response to the October 28, 2011 Presidential Memorandum (http://1.usa.gov/uHoAA4) that required federal agencies to streamline
Researchers have launched a clinical trial at the NIH Clinical Center to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). DEX-M74, based on an NIH technology, is being developed through a collaboration between the